/
RSS Feed
Stuart Pocock
REFERENCE: ABSTRACT N Engl J Med 2007; 357: 28-381
STUART POCOCK, London School of Hygiene and Tropical Medicine
Reassuring findings about the safety of the anti-diabetic drug rosiglitazone have been published in the New England Journal of Medicine following an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. This latest publication follows a meta-analysis in June 2007 by Nissen and Wolski which raised doubt about the safety of the drug. Nicola Solomon spoke with the RECORD trial’s statistician, Stuart Pocock, to get the latest data from this largest study specifically designed to look at cardiovascular outcomes.
STUART POCOCK, London School of Hygiene and Tropical Medicine
Reassuring findings about the safety of the anti-diabetic drug rosiglitazone have been published in the New England Journal of Medicine following an interim analysis of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD) study. This latest publication follows a meta-analysis in June 2007 by Nissen and Wolski which raised doubt about the safety of the drug. Nicola Solomon spoke with the RECORD trial’s statistician, Stuart Pocock, to get the latest data from this largest study specifically designed to look at cardiovascular outcomes.
